ResMed (RMD) Reports In-Line Q4 EPS
Tweet
Share
E-mail
Get Alerts RMD Hot Sheet
Price: $221.64 -2.94%
EPS Growth %: +5.5%
Financial Fact:
Total other income, net: -1.22M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: +5.5%
Financial Fact:
Total other income, net: -1.22M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
ResMed (NYSE: RMD) reported Q4 EPS of $2.08, in-line with the analyst estimate of $2.08. Revenue for the quarter came in at $1.22 billion versus the consensus estimate of $1.22 billion.
For earnings history and earnings-related data on ResMed (RMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Explosions heard on Iran's Kharg island - MEHR
- ServiceTitan, Inc. (TTAN) Misses Q2 EPS by 1c, Offers Guidance
- Iran's recent attempts to hit American naval assets are raising alarms that regime is getting assistance from China or Russia - WSJ
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
